|
CEP350 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.12459999979109E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.54019999998312E-06 |
| Normal-vs-Stage2 |
5.54889999999642E-05 |
| Normal-vs-Stage3 |
1.699499999952E-06 |
| Normal-vs-Stage4 |
3.57210000000441E-05 |
| Stage1-vs-Stage2 |
5.003600E-01 |
| Stage1-vs-Stage3 |
4.545200E-01 |
| Stage1-vs-Stage4 |
5.185000E-01 |
| Stage2-vs-Stage3 |
9.127600E-01 |
| Stage2-vs-Stage4 |
9.682200E-01 |
| Stage3-vs-Stage4 |
9.458400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.79019999999331E-07 |
| Normal-vs-AfricanAmerican |
3.553800E-02 |
| Normal-vs-Asian |
1.72910999999276E-05 |
| Caucasian-vs-AfricanAmerican |
2.553000E-01 |
| Caucasian-vs-Asian |
5.217800E-01 |
| AfricanAmerican-vs-Asian |
1.202440E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.02189999970659E-07 |
| Normal-vs-Female |
5.53340000042368E-07 |
| Male-vs-Female |
6.917600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.56070000000486E-05 |
| Normal-vs-Age(41-60Yrs) |
1.67059999944819E-07 |
| Normal-vs-Age(61-80Yrs) |
1.95075999999128E-05 |
| Normal-vs-Age(81-100Yrs) |
1.777930E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.898850E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.807200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.408200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.739400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.643000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.967200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.898430E-01 |
| Classical-VS-Follicular |
1.069800E-02 |
| Classical-VS-Other |
1.920220E-01 |
| Classical-VS-Normal |
2.17129999999788E-05 |
| Tall-VS-Follicular |
7.402000E-01 |
| Tall-VS-Other |
5.045800E-01 |
| Tall-VS-Normal |
1.392550E-04 |
| Follicular-VS-Other |
6.938200E-01 |
| Follicular-VS-Normal |
4.61750000013694E-07 |
| Other-VS-Normal |
6.460700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.28880000297372E-08 |
| Normal-vs-N1 |
1.7944000000325E-06 |
| N0-vs-N1 |
7.209200E-01 |
|
|
